MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Our mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator annually features 100 companies that address one or more of the transformative themes identified in an annual survey of leading manufacturers and providers.
Nanotis is a company which Solve various problems in infectious disease tests such as influenza.
Nurami
Non Equity Assistance in 2024
Nurami Medical focuses on creating advanced surgical scaffolds aimed at enhancing the repair and regeneration of soft tissues following internal surgeries. Utilizing electrospinning technology, the company develops biomaterials and nanofiber-based matrices that improve patient outcomes in various surgical procedures. These matrices feature a porous scaffold that promotes tissue regeneration and incorporate a novel temperature-sensitive sealant designed to prevent pathogen entry and cerebrospinal fluid leaks. This innovative approach addresses critical needs in surgical treatment, providing surgeons with effective solutions for their patients.
Nanochon
Non Equity Assistance in 2024
Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.
NanoBioFAB
Non Equity Assistance in 2024
Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.
Alyve Medical
Non Equity Assistance in 2023
Manufacturers of innovative medical devices intended to incorporate sensors, both therapeutic and diagnostic, to help people overcome musculoskeletal problems. The company provides NMES (Neuromuscular Electrical Stimulation) devices that invoke neuroplasticity for optimal outcomes and offers medical devices for physical therapy and rehabilitation, thereby enabling patients to regain and improve their range of motion and function.
Avisi Technologies
Seed Round in 2019
Avisi Technologies Inc. is a company based in Philadelphia, Pennsylvania, that focuses on developing innovative solutions for glaucoma treatment. Founded in 2017, the company has created VisiPlate, a next-generation aqueous shunt that utilizes nanotechnology to provide a defense against blindness caused by glaucoma. This advanced technology aims to improve the effectiveness of glaucoma treatments and enhance patient outcomes.
Nanowear
Grant in 2017
Nanowear, Inc. specializes in the development of textile-based nanosensor technology that facilitates wireless and real-time electrophysiological monitoring. Founded in 2014 and headquartered in Brooklyn, New York, the company offers products such as SimplECG, a remote cardiac monitoring undergarment, and SimpleSense, which focuses on the monitoring and management of congestive heart failure. These garments collect multi-channel electrocardiogram (ECG), heart rate, and respiratory rate data, which is transmitted to a web-based portal accessible by healthcare professionals via a mobile application. Nanowear's technology serves various sectors, including cardiac and neurological health, industrial safety, government, sports medicine, and performance diagnostics, providing accurate and continuous diagnostic data in a cost-effective and unobtrusive manner. The company also maintains a research and development facility in University Park, Pennsylvania.
2C Tech
Grant in 2014
2C Tech specializes in the development of innovative therapeutic approaches for ophthalmic diseases, utilizing advanced nanoparticle and Quantum Dot technologies. The company aims to address unmet medical needs in patients suffering from retinal degenerative conditions, with a primary focus on creating a proprietary therapy for Retinitis Pigmentosa. In addition to Retinitis Pigmentosa, 2C Tech's technology has the potential to benefit patients with other serious conditions such as Macular Degeneration, Glaucoma, and Diabetic Retinopathy, which affect a larger population. By leveraging its unique expertise, 2C Tech strives to provide effective treatment options that can significantly improve patient outcomes in the field of ocular medicine.
Fibralign
Grant in 2014
Fibralign Corporation specializes in the development of advanced biomedical devices using its proprietary Nanoweave® scaffolding technology. This innovative approach allows Fibralign to create products that mimic human tissue structure, influencing cell behavior and collagen fiber orientation to support the body's regenerative processes. The company's first product, the BioBridge® Collagen Matrix, is currently undergoing clinical studies to assess its effectiveness in treating and preventing secondary lymphedema. Additionally, Fibralign is focused on research and development for new applications, including treatments for ischemia and novel delivery systems for stem cells and gene therapy.
HeadSense Medical
Grant in 2014
HeadSense Medical Ltd. is an early-stage company based in Netanya, Israel, focused on developing non-invasive diagnostic devices for brain health. Established in 2011, the company has created a validated and CE Mark approved intracranial pressure (ICP) monitor that is applicable in various medical fields, including neurosurgery, neurology, emergency medicine, and critical care. The device allows healthcare professionals to diagnose and monitor critical clinical parameters without the need for invasive procedures. In addition to its ICP monitor, HeadSense is actively working on expanding its product offerings to include diagnostic tools for cerebral vasospasm, concussion, and the quantification of traumatic brain injury severity, among others. The company operates in both the U.S. and Israel, aiming to enhance patient outcomes through innovative monitoring solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.